ArticleActa pharmaceutica Sinica. B2021
Simultaneous improvement to solubility and bioavailability of active natural compound isosteviol using cyclodextrin metal-organic frameworks.
Article in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 45 citations in OpenAlex.
- Crystal engineering for poorly water-soluble drugs: From design to applications.Acta pharmaceutica Sinica. B · 2026Review
- Integrated Experimental and Computational Insights into the Systematic Synthesis of Cyclodextrin-based MOF.ACS omega · 2026Article
- Exploration of covalent-organic frameworks and metal-organic frameworks for drug delivery applications.Frontiers in chemistry · 2026Review
- Metal-organic frameworks in pharmaceutical research.Pharmaceutical science advances · 2025Review
- Enhanced Encapsulation of Linalyl Acetate in Cyclodextrin-Based Metal-Organic Frameworks for Improved Stability.Molecules (Basel, Switzerland) · 2025Article
- Incorporation of Mometasone Furoate into a Cyclodextrin Metal-Organic Framework to Optimize Nasal Administration.Pharmaceutics · 2025Article
- The Co-Delivery of Natural Products and Small RNAs for Cancer Therapy: A Review.Molecules (Basel, Switzerland) · 2025Review
- γ-Cyclodextrin Metal-Organic Frameworks: Do Solvents Make a Difference?Molecules (Basel, Switzerland) · 2023Article
- Supramolecular nanomedicines based on host-guest interactions of cyclodextrins.Exploration (Beijing, China) · 2023Review
- Electrospun Food Polysaccharides Loaded with Bioactive Compounds: Fabrication, Release, and Applications.Polymers · 2023Review
- Advancement in Solubilization Approaches: A Step towards Bioavailability Enhancement of Poorly Soluble Drugs.Life (Basel, Switzerland) · 2023Review
- Synthesis and potential applications of cyclodextrin-based metal-organic frameworks: a review.Environmental chemistry letters · 2023Review
- The Systems of Naringenin with Solubilizers Expand Its Capability to Prevent Neurodegenerative Diseases.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclodextrin metal-organic framework (CD-MOF) as a highly porous supramolecular carrier could be one of the solutions to the insolubility of isosteviol (STV). The solubility of STV was lower than 20.00 ng/mL at pH 1.0 and pH 4.5, whilst its solubility increased to 20,074.30 ng/mL at pH 6.8 and 129.58 ng/mL in water with a significant pH-dependence. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.